Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2948 studies found for:    non-Hodgkin's lymphoma
Show Display Options
Download search resultsDownload the search results for:
non-Hodgkin's lymphoma (2948 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Recruiting A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: ABT-199;   Drug: Bendamustine;   Drug: Rituximab
2 Completed Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma
Conditions: Non-Hodgkin's Lymphoma;   Mantle Cell Lymphoma
Intervention: Drug: bendamustine hydrochloride
3 Completed Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Iodine I 131 Tositumomab
4 Completed SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: bendamustine and rituximab
5 Completed A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Everolmus
6 Completed
Has Results
Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL)
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Oxaliplatin
7 Withdrawn A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma
Condition: Relapsed/Refractory Non-Hodgkin's Lymphoma
Intervention: Drug: [14C]ABT-199 (GDC-0199)
8 Recruiting Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL
Conditions: Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Hodgkin Disease
Interventions: Biological: Antigen Escalation Stage;   Biological: Dose escalation study of T cells
9 Completed Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
Conditions: Multiple Myeloma;   Non-Hodgkin Lymphoma;   Hodgkin Disease
Intervention: Drug: TG-0054
10 Recruiting Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma
Conditions: Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma
Intervention: Drug: LBH589
11 Active, not recruiting Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Dasatinib
12 Terminated Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma
Conditions: Hodgkins Lymphoma;   Non-Hodgkin Lymphoma
Interventions: Genetic: LMP1 SPECIFIC CYTOTOXIC T-LYMPHOCYTES;   Genetic: LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTES
13 Terminated Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin’s Lymphoma and Solid Tumors
Conditions: Non-Hodgkin's Lymphoma,;   Solid Tumors
Intervention: Drug: PPI-2458
14 Completed Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy
Conditions: Chemotherapy-Induced Nausea and Vomiting;   Non Hodgkin's Lymphoma
Intervention: Drug: Palonosetron
15 Not yet recruiting Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL)
Conditions: Chronic Lymphocytic Leukaemia (CLL);   Indolent Non Hodgkin's Lymphoma (iNHL)
Intervention:
16 Recruiting Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma
Condition: Non Hodgkin's Lymphoma
Interventions: Drug: Rituximab;   Drug: Lenalidomide
17 Completed Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Zevalin-BuCyE
18 Recruiting Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
Condition: Indolent Non-Hodgkin's Lymphoma
Interventions: Biological: Arm A: Rituximab;   Biological: Arm B: GA101
19 Recruiting Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Conditions: Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   HIV-associated Hodgkin Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: lenalidomide;   Drug: temsirolimus;   Other: laboratory biomarker analysis
20 Active, not recruiting PEARL Study: Improvement of Non-Hodgkin's Lymphoma Care
Condition: Non-Hodgkin Lymphoma
Interventions: Other: Implementation tools;   Other: Standard intervention

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years